How Has the Non-Insulin Therapies For Diabetes Market Size Evolved in Recent Years?
The non-insulin therapies for diabetes market has seen considerable growth due to a variety of factors.
• The non-insulin therapies for diabetes market has seen strong growth in recent years. It will grow from $19.98 billion in 2024 to $21.41 billion in 2025, at a compound annual growth rate (CAGR) of 7.1%.
This growth can be attributed to the rising prevalence of diabetes, growing awareness of diabetes management, higher healthcare spending, lifestyle changes leading to more diabetes cases, increased diagnoses, government initiatives, and more investment in pharmaceutical R&D.
What Are The Predictions for The Non-Insulin Therapies For Diabetes Market in the Coming Years?
The non-insulin therapies for diabetes market is expected to maintain its strong growth trajectory in upcoming years.
• The non-insulin therapies for diabetes market is expected to experience strong growth, reaching $27.9 billion by 2029 with a CAGR of 6.8%.
This growth is driven by the increasing prevalence of diabetes, greater awareness of diabetes management, the adoption of combination therapies, an aging population, higher healthcare spending, and expanding telemedicine. Major trends include advances in oral and injectable medications, improvements in drug delivery systems, oral peptide delivery, telemedicine adoption, and combination therapies.
Which Drivers Are Accelerating Growth In The Non-Insulin Therapies For Diabetes Market?
The rise in diabetes cases is anticipated to spur the development of non-insulin treatments in the diabetes market. Diabetes, a long-term health condition, is typified by elevated blood sugar levels, arising when the body is unable to produce sufficient insulin or use it correctly. Sedentary lifestyles, unhealthy food habits, genetic factors, an aging population, obesity, ethnicity, a lack of awareness, restricted healthcare access, and environmental influences all contribute to the rising incidence of diabetes. Non-insulin diabetic treatments work by enhancing insulin receptiveness, curbing liver glucose production, raising muscle cell glucose intake, and boosting overall blood sugar control. For instance, as reported by The British Diabetic Association in April 2023, around 4.3 million people in the UK were diagnosed with diabetes. Registration data from 2021-22 reveals an uptick of 148,951 cases relative to 2020-21. Additionally, over 2.4 million individuals in the UK are at an elevated risk of contracting type 2 diabetes. Hence, the rising prevalence of diabetes is bolstering the expansion of non-insulin treatments within the diabetes market.
What Are The Core Segments Of The Global Non-Insulin Therapies For Diabetes Market?
The non-insulin therapies for diabetes market covered in this report is segmented –
1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Pre-Book The Non-Insulin Therapies For Diabetes Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Non-Insulin Therapies For Diabetes Market?
Large firms active in the diabetes non-insulin therapies market are creating bespoke diabetes management systems. These systems aim to improve patient results by enabling real-time tracking, data analysis, and tailored treatment options. A personalized diabetes management system modifies the treatment and monitoring based on the individual needs of each patient. These alterations use real-time data and analytics to elevate care quality and outcomes. For example, in November 2022, Eli Lilly and Company, a pharmaceutical company based in the United States, introduced the Tempo personalized diabetes management platform. The platform is composed of three key features: the Tempo Smart Button, the TempoSmart application, and finally, the pre-loaded insulin pen known as the Tempo Pen. Together, these features create a synergistic effect, offering customized advice for adults living with diabetes. The technology is geared towards assisting adults dealing with type 1 or type 2 diabetes and their healthcare providers. It does so by enabling them to make educated, data-led decisions regarding the use of Lilly insulins in their treatment.
Who Are the Key Players In The Non-Insulin Therapies For Diabetes Market?
Major companies operating in the non-insulin therapies for diabetes market are:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Sanofi
• The Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Les Servier Laboratories
• Sumitomo Dainippon Pharma Co. Ltd.
• Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
• Uni-Bio Science Group Ltd.
• Intarcia Therapeutics
• Janssen Pharmaceuticals
• Boan Biotech
• SatRx LLC
What Are The Regional Insights Into The Non-Insulin Therapies For Diabetes Market?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
